Advertisement

 

 

Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies.

Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies.
Author Information (click to view)

Wang J, Garancher A, Ramaswamy V, Wechsler-Reya RJ,


Wang J, Garancher A, Ramaswamy V, Wechsler-Reya RJ, (click to view)

Wang J, Garancher A, Ramaswamy V, Wechsler-Reya RJ,

Advertisement

Annual review of neuroscience 2018 04 11() doi 10.1146/annurev-neuro-070815-013838

Abstract

Brain tumors are the leading cause of cancer-related death in children, and medulloblastoma (MB) is the most common malignant pediatric brain tumor. Advances in surgery, radiation, and chemotherapy have improved the survival of MB patients. But despite these advances, 25-30% of patients still die from the disease, and survivors suffer severe long-term side effects from the aggressive therapies they receive. Although MB is often considered a single disease, molecular profiling has revealed a significant degree of heterogeneity, and there is a growing consensus that MB consists of multiple subgroups with distinct driver mutations, cells of origin, and prognosis. Here, we review recent progress in MB research, with a focus on the genes and pathways that drive tumorigenesis, the animal models that have been developed to study tumor biology, and the advances in conventional and targeted therapy. Expected final online publication date for the Annual Review of Neuroscience Volume 41 is July 8, 2018. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Submit a Comment

Your email address will not be published. Required fields are marked *

15 − eight =

[ HIDE/SHOW ]